Review
Biochemistry & Molecular Biology
Cecilia Zavala-Tecuapetla, Hiram Luna-Munguia, Maria-Leonor Lopez-Meraz, Manola Cuellar-Herrera
Summary: This article provides an overview of the potential of cannabidiol (CBD) in treating epilepsy, including its pharmacological characteristics, interactions with molecular targets, and preclinical research on its anti-seizure effects in acute and chronic seizure models. Furthermore, it highlights the attention given to other natural cannabinoids and synthetic derivatives of CBD as potential therapeutic compounds for epilepsy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Zsolt Gall, Krisztina Kelemen, Andrea Tolokan, Istvan Zolcseak, Istvan Savel, Reka Bod, Elek Ferencz, Szende Vancea, Melinda Urkon, Melinda Kolcsar
Summary: This study examines the effects of long-term CBD treatment in the PTZ-kindling model of epilepsy. The results show that CBD treatment decreases mortality rate and prolongs seizure latency, but also leads to cognitive impairment.
Article
Veterinary Sciences
Tom Jukier, Crisanta Cruz-Espindola, Doug Martin, Dawn M. Boothe
Summary: The historical use of marijuana for medicinal purposes includes its use in the treatment of epilepsy. Recently, a highly purified cannabidiol medication has been approved by the FDA for add-on therapy in certain forms of epilepsy. This study focused on determining the disposition of a single dose of cannabidiol in healthy cats, both in fed and fasted states. The pharmacokinetic analysis showed that cannabidiol has a significantly higher bioavailability when administered in a fed state compared to a fasted state, indicating its potential therapeutic value for epilepsy in cats.
FRONTIERS IN VETERINARY SCIENCE
(2023)
Article
Pharmacology & Pharmacy
Ilaria Ammendolia, Carmen Mannucci, Luigi Cardia, Gioacchino Calapai, Sebastiano Gangemi, Emanuela Esposito, Fabrizio Calapai
Summary: This article analyzes serious case reports on suspected adverse reactions to CBD as an antiepileptic drug found in the EudraVigilance database. The most frequent serious adverse reactions include epilepsy aggravation, hepatic disorders, lack of efficacy, and somnolence. Precautions such as monitoring drug interactions, epilepsy aggravation, and drug effectiveness should be taken into consideration for the appropriate use of CBD as an antiepileptic.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Medicine, General & Internal
Asra Fazlollahi, Mahdi Zahmatyar, Mahta ZareDini, Behnam Golabi, Seyed Aria Nejadghaderi, Mark J. M. Sullman, Koroush Gharagozli, Ali-Asghar Kolahi, Saeid Safiri
Summary: This systematic review and meta-analysis investigated the frequency and risk of adverse events (AEs) in patients with epilepsy using cannabidiol (CBD). The study found that the use of CBD was associated with an increased risk of AEs. Additional studies are needed to determine the safe and effective CBD dosage for treating epilepsy.
Article
Nutrition & Dietetics
Xiaoxiang Gong, Lingjuan Liu, Xingfang Li, Jie Xiong, Jie Xu, Dingan Mao, Liqun Liu
Summary: This study investigates the effects of cannabidiol (CBD) on the gut microbiota and metabolic profile of epileptic rats. The results show that CBD can alleviate dysbiosis of gut microbiota and metabolic disorders in epileptic rats. The study suggests that the attenuation of epilepsy in rats by CBD may be related to gut microbial abundance and metabolite levels. This research provides valuable scientific insights into the regulatory pathway of CBD in alleviating epilepsy.
FRONTIERS IN NUTRITION
(2022)
Review
Neurosciences
Ashna Talwar, Emily Estes, Rajender Aparasu, Doodipala Samba Reddy
Summary: This study evaluated the clinical potential of oral CBD in treating refractory epilepsy through a systematic review and meta-analysis. The results suggest that CBD treatment is more effective than placebo in reducing seizures in patients with refractory epilepsy, although it is associated with increased adverse events. CBD shows promise as a standalone or adjunct therapy for controlling seizures, but further investigation and guidelines are needed.
EXPERIMENTAL NEUROLOGY
(2023)
Article
Pharmacology & Pharmacy
Lindsey Shapiro, Andrew Escayg, Jennifer C. Wong
Summary: Voltage-gated sodium channel genes are important for human epilepsy. SCN8A mutations can cause various clinical symptoms, including different types of seizures, movement disorders, intellectual disabilities, and autism. CBD treatment in RL/+ mutant mice showed dose-dependent seizure resistance and improved social behavior and reduced hyperactivity. CBD may be beneficial for patients with SCN8A-associated disease.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biology
Gabriela Pesantez Rios, Luciana Armijos Acurio, Ruth Jimbo Sotomayor, Victor Cueva, Ximena Pesantez Rios, Hugo Navarrete Zambrano, Samuel Pascual, Galo Pesantez Cuesta
Summary: This retrospective observational study demonstrates that long-term use of CBD as an adjuvant therapy significantly reduces the frequency, duration, and type of seizures in patients with drug-resistant epilepsy. This is especially effective in improving the most incapacitating seizures, improving the quality of life for patients and their families.
Review
Plant Sciences
Mario Vallejo-Marin
Summary: Bees produce different types of vibrations, including buzz pollination, through vibrations. Bees can control the characteristics of buzz pollination by adjusting the biomechanical properties of their thorax, in order to optimize energy use and pollen collection.
JOURNAL OF EXPERIMENTAL BOTANY
(2022)
Review
Psychiatry
Rafael M. Bitencourt, Reinaldo N. Takahashi, Elisaldo A. Carlini
Summary: Cannabis and its derivatives, especially CBD, have shown promising potential in the treatment of epilepsy and various neuropsychiatric disorders, with pre-clinical and clinical studies providing strong evidence for their anticonvulsant properties and therapeutic effects in different conditions.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Behavioral Sciences
Hakan Silek, Ozgur Bilgin Topcuoglu
Summary: This study aimed to investigate the quality and reliability of YouTube videos regarding the use of CBD oil for epilepsy treatment. A total of 100 videos were evaluated by two experienced neurologists and various indicators were recorded. The results showed that 32% of the videos were poor, 43% were moderate, and only 25% were good in terms of quality and reliability. Therefore, strict auditing of YouTube videos related to health issues is necessary before they can be made publicly accessible.
EPILEPSY & BEHAVIOR
(2023)
Review
Neurosciences
Doodipala Samba Reddy
Summary: This article provides an overview of the clinical utility and efficacy of cannabidiol (CBD) as a treatment for refractory and rare forms of epilepsy. CBD has shown to be a safe and effective antiseizure medicine with multiple mechanisms of action. However, there are still challenges and risks associated with its widespread use.
EXPERIMENTAL NEUROLOGY
(2023)
Article
Clinical Neurology
Paulo Caceres Guido, Natalia Riva, Roberto Caraballo, Gabriela Reyes, Marina Huaman, Robinson Gutierrez, Silvana Agostini, Sandra Fabiana Delaven, Carlos A. Perez Montilla, Facundo Garcia Bournissen, Paula Schaiquevich
Summary: This study characterized the pharmacokinetics of CBD in pediatric patients with refractory epileptic encephalopathy, showing that CBD systemic exposure parameters were in the lower range and most patients had little CBD plasma level fluctuation. The administration of CBD was generally safe and well tolerated, with a novel drug interaction recorded. Large interindividual variability in CBD exposure was observed, encouraging the use of CBD therapeutic drug monitoring.
Article
Behavioral Sciences
Silvia Kochen, Manuela Villanueva, Liliana Bayarres, Anilu Daza-Restrepo, Silvia Gonzalez Martinez, Silvia Oddo
Summary: A study conducted in Argentina found that adjuvant treatment with cannabidiol oil (CBD) in adult patients with drug-resistant focal epilepsy was effective, safe, well tolerated, and associated with a significant improvement in their quality of life.
EPILEPSY & BEHAVIOR
(2023)
